Diagnosing complications following cochlear implantation using transcutaneous ultrasound.


Journal

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 25 08 2021
accepted: 05 10 2021
pubmed: 28 10 2021
medline: 7 7 2022
entrez: 27 10 2021
Statut: ppublish

Résumé

The aim of this study was to investigate the feasibility and reliability of transcutaneous ultrasound for the detection of complications after cochlear implantation. In a single center retrospective cohort study, 115 consecutive cases of suspected complications after cochlear implantation (intervention group) were examined. The rate of pathologic ultrasound findings for specific leading symptoms and diagnoses was compared to a control group comprising twenty consecutive cochlear implants in symptom-free patients. Diagnostic ultrasound showed distinctly more pathologic findings in the intervention group (n = 67; 58.3%; p < 0.001) compared to the control group (n = 1; 5%). Ultrasound revealed significantly more pathologic findings in haematoma or seroma around the implant (n = 17; 100%; p < 0.001; ϕ = 0.94) and magnet dislocation (n = 44; 97.7%; p < 0.001; ϕ = 0.92) confirmed by a strong effect. Ultrasound examination showed a medium to high effect size in patients presenting with local infections (n = 3; 21.4%; p = 0.283; ϕ = 0.25) and skin flap oedema (n = 2; 50%; p = 0.061; ϕ = 0.51). In contrast, ultrasound examinations displayed a low effect size in undefined cephalgia (0%; p = 0.444; ϕ = 0.17) and device malfunction or failure (0%; p > 0.999; ϕ = 0.13). Transcutaneous ultrasound can be advocated as a feasible and effective method in the diagnostic work-up of magnet dislocation and haematoma or seroma around the implant following cochlear implantation. Contrary, ultrasound findings can be expected to be inconspicuous in patients presenting with undefined cephalgia and device malfunction or failure.

Identifiants

pubmed: 34704135
doi: 10.1007/s00405-021-07128-2
pii: 10.1007/s00405-021-07128-2
pmc: PMC9444831
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3867-3873

Informations de copyright

© 2021. The Author(s).

Références

J Clin Ultrasound. 2017 Oct;45(8):515-519
pubmed: 28369924
Acta Otolaryngol. 2021 Feb;141(2):111-116
pubmed: 33045882
Otol Neurotol. 2016 Oct;37(9):1284-90
pubmed: 27525711
Acta Otolaryngol. 2010;130(1):108-13
pubmed: 19452335
JAMA Otolaryngol Head Neck Surg. 2015 Nov;141(11):1012-7
pubmed: 26469680
J Laryngol Otol. 2013 Aug;127(8):802-4
pubmed: 23834762
Laryngoscope. 2021 Mar;131(3):E940-E945
pubmed: 32484949
Otol Neurotol. 2017 Aug;38(7):956-961
pubmed: 28604577
Otol Neurotol. 2021 Jun 1;42(5):e536-e542
pubmed: 33534388
Cochlear Implants Int. 2015 Jan;16(1):47-50
pubmed: 24950760
Cochlear Implants Int. 2021 Jul;22(4):195-202
pubmed: 33576730
Eur Arch Otorhinolaryngol. 2020 May;277(5):1297-1304
pubmed: 32008075
Int J Pediatr Otorhinolaryngol. 2014 Jul;78(7):1040-4
pubmed: 24809767
Laryngoscope. 2015 Aug;125(8):1946-51
pubmed: 25823594
Clin Radiol. 2019 Dec;74(12):972.e9-972.e16
pubmed: 31324337
Radiologe. 2019 Jan;59(1):48-56
pubmed: 30350108
N Engl J Med. 2020 Apr 16;382(16):1531-1542
pubmed: 32294347
Otol Neurotol. 2020 Oct;41(9):e1098-e1104
pubmed: 32925844
Eur Arch Otorhinolaryngol. 2020 Jul;277(7):1917-1923
pubmed: 32185500
Arch Otolaryngol Head Neck Surg. 2010 Jan;136(1):12-5
pubmed: 20083771
HNO. 2017 Jan;65(Suppl 1):35-40
pubmed: 26886493
Otol Neurotol. 2021 Mar 1;42(3):408-413
pubmed: 33351564
Int J Pediatr Otorhinolaryngol. 2019 May;120:64-67
pubmed: 30771555
Ann Otol Rhinol Laryngol Suppl. 1995 Sep;166:420-2
pubmed: 7668733
Dtsch Arztebl Int. 2020 Oct 9;117(41):690-700
pubmed: 33357341
Otol Neurotol. 2021 Jan;42(1):51-58
pubmed: 33044338
Otol Neurotol. 2005 Mar;26(2):202-4
pubmed: 15793405

Auteurs

Robin Rupp (R)

Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Waldstraße 1, 91054, Erlangen, Germany. robin.rupp@uk-erlangen.de.

Vivian Thimsen (V)

Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Waldstraße 1, 91054, Erlangen, Germany.

Matthias Balk (M)

Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Waldstraße 1, 91054, Erlangen, Germany.

Sarina K Mueller (SK)

Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Waldstraße 1, 91054, Erlangen, Germany.

Matti Sievert (M)

Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Waldstraße 1, 91054, Erlangen, Germany.

Konstantinos Mantsopoulos (K)

Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Waldstraße 1, 91054, Erlangen, Germany.

Ulrich Hoppe (U)

Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Waldstraße 1, 91054, Erlangen, Germany.

Joachim Hornung (J)

Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Waldstraße 1, 91054, Erlangen, Germany.

Heinrich Iro (H)

Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Waldstraße 1, 91054, Erlangen, Germany.

Antoniu-Oreste Gostian (AO)

Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Waldstraße 1, 91054, Erlangen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH